AP2001002036A0 - Use of glucose uptake enhancer for reducing apoptosis. - Google Patents

Use of glucose uptake enhancer for reducing apoptosis.

Info

Publication number
AP2001002036A0
AP2001002036A0 APAP/P/2001/002036A AP2001002036A AP2001002036A0 AP 2001002036 A0 AP2001002036 A0 AP 2001002036A0 AP 2001002036 A AP2001002036 A AP 2001002036A AP 2001002036 A0 AP2001002036 A0 AP 2001002036A0
Authority
AP
ARIPO
Prior art keywords
glucose uptake
uptake enhancer
human
cells
reducing apoptosis
Prior art date
Application number
APAP/P/2001/002036A
Other languages
English (en)
Inventor
Antoine Michel Alain Bril
Robin Edwin Buckingham
Nassirah Khandoudi
Original Assignee
Smithkline Beecham Plc
Smithkline Beecham Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9815871.0A external-priority patent/GB9815871D0/en
Priority claimed from GBGB9815872.8A external-priority patent/GB9815872D0/en
Priority claimed from GBGB9905387.8A external-priority patent/GB9905387D0/en
Application filed by Smithkline Beecham Plc, Smithkline Beecham Lab filed Critical Smithkline Beecham Plc
Publication of AP2001002036A0 publication Critical patent/AP2001002036A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
APAP/P/2001/002036A 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis. AP2001002036A0 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB9815871.0A GB9815871D0 (en) 1998-07-21 1998-07-21 Novel compound
GBGB9815872.8A GB9815872D0 (en) 1998-07-21 1998-07-21 Novel method
GBGB9905387.8A GB9905387D0 (en) 1999-03-09 1999-03-09 Novel method
PCT/GB1999/002361 WO2000004890A1 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis

Publications (1)

Publication Number Publication Date
AP2001002036A0 true AP2001002036A0 (en) 2001-03-31

Family

ID=27269407

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002036A AP2001002036A0 (en) 1998-07-21 1999-07-21 Use of glucose uptake enhancer for reducing apoptosis.

Country Status (25)

Country Link
EP (2) EP1098639B1 (enExample)
JP (1) JP2002521326A (enExample)
KR (1) KR20010079551A (enExample)
CN (1) CN1310620A (enExample)
AP (1) AP2001002036A0 (enExample)
AT (1) ATE288746T1 (enExample)
AU (1) AU5053799A (enExample)
BG (1) BG105250A (enExample)
BR (1) BR9912117A (enExample)
CA (1) CA2338211A1 (enExample)
DE (1) DE69923687T2 (enExample)
DK (1) DK1098639T3 (enExample)
EA (1) EA200100165A1 (enExample)
ES (1) ES2237929T3 (enExample)
HU (1) HUP0103199A3 (enExample)
ID (1) ID26986A (enExample)
IL (1) IL140664A0 (enExample)
NO (1) NO20010292L (enExample)
OA (1) OA11579A (enExample)
PL (1) PL345627A1 (enExample)
PT (1) PT1098639E (enExample)
SI (1) SI1098639T1 (enExample)
SK (1) SK1012001A3 (enExample)
TR (1) TR200100207T2 (enExample)
WO (1) WO2000004890A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000043006A1 (en) * 1999-01-19 2000-07-27 Sankyo Company, Limited Inhibitor for nerve cell death due to glutamic acid cytotoxicity
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10199003I1 (de) * 1987-09-04 2003-06-12 Beecham Group Plc Substituierte Thiazolidinionderivate
JPH05202042A (ja) * 1992-01-24 1993-08-10 Sankyo Co Ltd 糖尿病性合併症治療剤
GB9218830D0 (en) * 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
IL120443A (en) * 1996-03-18 2000-07-16 Sankyo Co Use of an insulin sensitizer for the manufacture of a medicament for the treatment or prophylaxis of pancreatitis
GB9611947D0 (en) * 1996-06-07 1996-08-07 Glaxo Group Ltd Medicaments
US6277819B1 (en) * 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
EP0958818A1 (en) * 1996-09-12 1999-11-24 Sankyo Company Limited Glutathione reductase activity potentiator containing troglitazone
GB9721692D0 (en) * 1997-10-13 1997-12-10 Smithkline Beecham Plc Novel treatment
DE69834508T2 (de) * 1997-11-19 2006-11-23 Takeda Pharmaceutical Co. Ltd. Apoptoseinhibitoren
AU2781899A (en) * 1998-02-24 1999-09-15 Trustees Of The University Of Pennsylvania, The Use of a cardiac purinoceptor to effect cellular glucose uptake
AU4005299A (en) * 1998-05-19 1999-12-06 Regents Of The University Of California, The Thiazolidine and oxazolidine derivatives for the treatment of acute myocardial infarction and inhibition of cardiomyocyte apoptosis
US5968960A (en) * 1999-01-14 1999-10-19 The Regents Of The University Of California Use of thiazolidinediones to ameliorate the adverse consequences of myocardial ischemia on myocardial function and metabolism

Also Published As

Publication number Publication date
HUP0103199A2 (hu) 2002-05-29
DE69923687D1 (de) 2005-03-17
NO20010292D0 (no) 2001-01-18
AU5053799A (en) 2000-02-14
TR200100207T2 (tr) 2001-05-21
CN1310620A (zh) 2001-08-29
EP1098639A1 (en) 2001-05-16
EP1098639B1 (en) 2005-02-09
HK1037865A1 (en) 2002-02-22
JP2002521326A (ja) 2002-07-16
NO20010292L (no) 2001-03-08
SI1098639T1 (enExample) 2005-08-31
SK1012001A3 (en) 2001-08-06
ATE288746T1 (de) 2005-02-15
CA2338211A1 (en) 2000-02-03
BG105250A (en) 2001-11-30
KR20010079551A (ko) 2001-08-22
PT1098639E (pt) 2005-06-30
ID26986A (id) 2001-02-22
WO2000004890A1 (en) 2000-02-03
IL140664A0 (en) 2002-02-10
EA200100165A1 (ru) 2001-08-27
ES2237929T3 (es) 2005-08-01
OA11579A (en) 2004-06-01
PL345627A1 (en) 2002-01-02
DK1098639T3 (da) 2005-06-13
HUP0103199A3 (en) 2002-08-28
DE69923687T2 (de) 2006-04-06
EP1516617A2 (en) 2005-03-23
BR9912117A (pt) 2001-04-10

Similar Documents

Publication Publication Date Title
GR20010300044T1 (en) Transfected cells and methods for treating diabetes
IL142824A0 (en) Lipoic acid derivatives and their use in treatment of disease
PL341300A1 (en) Non-dissolvable compositions for monitoring glucose level in blood
ZA992005B (en) Proton donating actives in absorbent articles.
AU3882599A (en) Vascular graft assemblies and methods for implanting same
MY108685A (en) Absorbing products having integral transverse retaining tab and pocket.
AU1941301A (en) Implantable nickel-free stainless steel stents
IL138871A0 (en) Flushable diaper and method
ZA200104934B (en) Refastenable and adjustable fastener system for diaper.
ZA993777B (en) Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases.
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
ZA991053B (en) Method and composition for treatment of inflammatory conditions.
EP0671768A3 (en) Improvements in or regarding electrodes for LSI.
AP2001002036A0 (en) Use of glucose uptake enhancer for reducing apoptosis.
ZA992192B (en) Humectant and lubricant solution for ophthalmic use.
AU1765300A (en) Compositions and methods for reducing or preventing fertilization in fish and birds
HUP0102652A3 (en) Method for treating sugar beet
ZA200003926B (en) Topiramate and related derivatives for treating Schizophrenia.
AR020614A1 (es) Nuevo metodo
Talati et al. Phenol and Methyl Phenols(Cresols) as Corrosion Inhibitors for Al-Cu Alloy in NaOH
WO2001038567A3 (en) Genetic indicators of tobacco consumption
ES1044936Y (es) Guia con efecto dotter para angioplastia y stent directo.
AU1382001A (en) Panty with side opening in crotch
ECSP993063A (es) Nuevo metodo para reducir o prevenir la apoptosis de celulas diferenciadas
EP0909170A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE USING ENANTIOMERIC ENRICHED (S) -TRIDIHEXETHYL